Company intelligence / Profile preview
Apimeds Pharmaceuticals US, Inc.
Matawan, New Jersey, United Statesapimedsus.com ↗
- Ownership
- Public · APUS
- Employees
- ~2
- Development stage
- Other
01
Overview
Apimeds previously conducted a Phase 3 trial for knee osteoarthritis with approximately 330 patients, which demonstrated clinical efficacy and safety in a US population. However, the FDA determined in 2018 that a second confirmatory Phase 3 trial was needed because the study population was too small and the methods for handling missing data were inadequate.
- Therapeutic areas
- Rheumatology
- Modalities
- ToxinBee venom-based toxin
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Financials
- Market cap
- $4.1M
- Total revenue
- $0
- Enterprise value
- $18.4M
Beyond the preview
Go deeper on Apimeds Pharmaceuticals US, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apimeds Pharmaceuticals US, Inc..